Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 28:13:924942.
doi: 10.3389/fendo.2022.924942. eCollection 2022.

Architects of Pituitary Tumour Growth

Affiliations
Review

Architects of Pituitary Tumour Growth

Maria Eugenia Sabatino et al. Front Endocrinol (Lausanne). .

Abstract

The pituitary is a master gland responsible for the modulation of critical endocrine functions. Pituitary neuroendocrine tumours (PitNETs) display a considerable prevalence of 1/1106, frequently observed as benign solid tumours. PitNETs still represent a cause of important morbidity, due to hormonal systemic deregulation, with surgical, radiological or chronic treatment required for illness management. The apparent scarceness, uncommon behaviour and molecular features of PitNETs have resulted in a relatively slow progress in depicting their pathogenesis. An appropriate interpretation of different phenotypes or cellular outcomes during tumour growth is desirable, since histopathological characterization still remains the main option for prognosis elucidation. Improved knowledge obtained in recent decades about pituitary tumorigenesis has revealed that this process involves several cellular routes in addition to proliferation and death, with its modulation depending on many signalling pathways rather than being the result of abnormalities of a unique proliferation pathway, as sometimes presented. PitNETs can display intrinsic heterogeneity and cell subpopulations with diverse biological, genetic and epigenetic particularities, including tumorigenic potential. Hence, to obtain a better understanding of PitNET growth new approaches are required and the systematization of the available data, with the role of cell death programs, autophagy, stem cells, cellular senescence, mitochondrial function, metabolic reprogramming still being emerging fields in pituitary research. We envisage that through the combination of molecular, genetic and epigenetic data, together with the improved morphological, biochemical, physiological and metabolically knowledge on pituitary neoplastic potential accumulated in recent decades, tumour classification schemes will become more accurate regarding tumour origin, behaviour and plausible clinical results.

Keywords: cellular fates; cellular physiology; pituitary gland; tumour growth; tumour growth suppression.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as being a potential conflict of interest.

Figures

Figure 1
Figure 1
New approaches for pituitary tumorigenic models. PitNETs can display intrinsic heterogeneity and cell subpopulations with diverse biological, genetic and epigenetic particularities, including tumorigenic potential. Tissue architecture and microenvironment could play vital roles in neoplasms. Like an architect who determines the use of materials at a building site, different cellular processes modify the structure and interactions within the gland, thereby shaping tumour growth. Obtaining a better understanding of PitNET growth requires new approaches and systematization of the available data through the combination of molecular, genetic and epigenetic data, together with the utilization of morphological, biochemical, physiological and metabolic knowledge about pituitary neoplastic potential.

Similar articles

Cited by

References

    1. Daly AF, Beckers A. The Epidemiology of Pituitary Adenomas. Endocrinol Metab Clin North Am (2020) 49:347–55. doi: 10.1016/j.ecl.2020.04.002 - DOI - PubMed
    1. Stalla GK, Renner U, Elguero MB, Arzt E. Molecular and Cellular Pathogenesis of Pituitary Tumors. Curr Opin Endocrine Metab Res (2018) 1:8. doi: 10.1016/j.coemr.2018.01.004 - DOI
    1. Shan B, Gerez J, Haedo M, Fuertes M, Theodoropoulou M, Buchfelder M, et al. . RSUME is Implicated in HIF-1-Induced VEGF-A Production in Pituitary Tumour Cells. Endocr Relat Cancer (2012) 19:13–27. doi: 10.1530/ERC-11-0211 - DOI - PubMed
    1. He W, Huang L, Shen X, Yang Y, Wang D, Yang Y, et al. . Relationship Between RSUME and HIF-1alpha/VEGF-A With Invasion of Pituitary Adenoma. Gene (2017) 603:54–60. doi: 10.1016/j.gene.2016.12.012 - DOI - PubMed
    1. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol (2022) 33:6–26. doi: 10.1007/s12022-022-09703-7 - DOI - PubMed

Publication types